公开(公告)号：US08895526B2

公开(公告)日：2014-11-25

申请号：US13260540

申请日：2010-03-29

申请人： Bruce Stillman ,  Scott W. Lowe ,  Anthony Mazurek ,  Johannes Ekkehart Zuber ,  Christopher Vakoc ,  Katherine McJunkin

发明人： Bruce Stillman ,  Scott W. Lowe ,  Anthony Mazurek ,  Johannes Ekkehart Zuber ,  Christopher Vakoc ,  Katherine McJunkin

IPC分类号： C12N15/11 ,  A01K67/027

CPC分类号： A61K31/185 ,  A01K67/0271 ,  A01K2207/05 ,  A01K2207/12 ,  A01K2227/105 ,  A01K2267/0331 ,  A01K2267/0393 ,  C12N15/111 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/11 ,  C12N2330/51 ,  C12N2799/027 ,  C12N2830/003 ,  C12N2840/203

摘要： Provided is a mosaic mouse model for use in determining the potency of an shRNA in vivo for reducing survival of cancer cells of chemotherapy-resistant leukemia. The syngeneic mouse recipient is transplanted with tet-on competent leukemia cells carrying a bicistronic nucleic acid construct comprising a promoter operably linked to a fusion gene associated with chemotherapy-resistant leukemia, and a sequence encoding a reverse tet-transactivator protein, such that both coding sequences are co-expressed from the promoter. Also provided are methods of treating soft tissue cancers.

摘要翻译： 提供了一种用于确定shRNA在体内用于降低化疗耐药性白血病癌细胞存活的效力的镶嵌小鼠模型。 将携带双顺反子核酸构建体的tet-on感受态白血病细胞移植到同基因小鼠受体中，所述双顺反子核酸构建体包含可操作地连接于与耐化学药物性白血病相关的融合基因的启动子，以及编码反向tet-transactivator蛋白的序列， 序列由启动子共表达。 还提供了治疗软组织癌症的方法。

公开(公告)号：US20120272346A1

公开(公告)日：2012-10-25

申请号：US13260540

申请日：2010-03-29

申请人： Bruce Stillman ,  Scott W. Lowe ,  Anthony Mazurek ,  Johannes Ekkehart Zuber ,  Christopher Vakoc ,  Katherine McJunkin

发明人： Bruce Stillman ,  Scott W. Lowe ,  Anthony Mazurek ,  Johannes Ekkehart Zuber ,  Christopher Vakoc ,  Katherine McJunkin

IPC分类号： A61K31/7088 ,  A61K49/00 ,  A61P35/02 ,  A01K67/027

CPC分类号： A61K31/185 ,  A01K67/0271 ,  A01K2207/05 ,  A01K2207/12 ,  A01K2227/105 ,  A01K2267/0331 ,  A01K2267/0393 ,  C12N15/111 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/11 ,  C12N2330/51 ,  C12N2799/027 ,  C12N2830/003 ,  C12N2840/203

摘要： Provided is a mosaic mouse model for use in determining the potency of an shRNA in vivo for reducing survival of cancer cells of chemotherapy-resistant leukemia. The syngeneic mouse recipient is transplanted with tet-on competent leukemia cells carrying a bicistronic nucleic acid construct comprising a promoter operably linked to a fusion gene associated with chemotherapy-resistant leukemia, and a sequence encoding a reverse tet-transactivator protein, such that both coding sequences are co-expressed from the promoter. Also provided are methods of treating soft tissue cancers.

摘要翻译： 提供了一种用于确定shRNA在体内用于降低化疗耐药性白血病癌细胞存活的效力的镶嵌小鼠模型。 将携带双顺反子核酸构建体的tet-on感受态白血病细胞移植到同基因小鼠受体中，所述双顺反子核酸构建体包含可操作地连接于与耐化学药物性白血病相关的融合基因的启动子，以及编码反向tet-transactivator蛋白的序列， 序列由启动子共表达。 还提供了治疗软组织癌症的方法。